CD8+ T-cell exhaustion: Impediment to triple-negative breast cancer (TNBC) immunotherapy

IF 9.7 1区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Biochimica et biophysica acta. Reviews on cancer Pub Date : 2024-10-15 DOI:10.1016/j.bbcan.2024.189193
Dandan Feng , Dongqing Pu , Jinlu Ren , Ming Liu , Zhen Zhang , Zhiyong Liu , Jingwei Li
{"title":"CD8+ T-cell exhaustion: Impediment to triple-negative breast cancer (TNBC) immunotherapy","authors":"Dandan Feng ,&nbsp;Dongqing Pu ,&nbsp;Jinlu Ren ,&nbsp;Ming Liu ,&nbsp;Zhen Zhang ,&nbsp;Zhiyong Liu ,&nbsp;Jingwei Li","doi":"10.1016/j.bbcan.2024.189193","DOIUrl":null,"url":null,"abstract":"<div><div>CD8<sup>+</sup> T-cell exhaustion has been identified as a significant contributor to immunosuppression and immune escape in triple-negative breast cancer (TNBC). Dysfunction due to cell exhaustion is characterized by reduced effector capacity and sustained expression of inhibitory receptors (IRs). The factors contributing to CD8<sup>+</sup> T-cell exhaustion are multifaceted, encompassing external influences such as the upregulation of IRs, reduction of effector cytokines, and internal changes within the immune cell, including transcriptomic alterations, epigenetic landscape remodeling, and metabolomic shifts. The impact of the altered TNBC tumor microenvironment (TME) on Tex is also a critical consideration. The production of exhausted CD8<sup>+</sup> T-cells (CD8<sup>+</sup> Tex) is positively correlated with poor prognosis and reduced response rates to immunotherapy in TNBC patients, underscoring the urgent need for the development of novel TNBC immunotherapeutic strategies that target the mechanisms of CD8<sup>+</sup> T-cell exhaustion. This review delineates the dynamic trajectory of CD8<sup>+</sup> T-cell exhaustion development in TNBC, provides an update on the latest research advancements in understanding its pathogenesis, and offers insights into potential immunotherapeutic strategies.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1879 6","pages":"Article 189193"},"PeriodicalIF":9.7000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochimica et biophysica acta. Reviews on cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304419X24001240","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

CD8+ T-cell exhaustion has been identified as a significant contributor to immunosuppression and immune escape in triple-negative breast cancer (TNBC). Dysfunction due to cell exhaustion is characterized by reduced effector capacity and sustained expression of inhibitory receptors (IRs). The factors contributing to CD8+ T-cell exhaustion are multifaceted, encompassing external influences such as the upregulation of IRs, reduction of effector cytokines, and internal changes within the immune cell, including transcriptomic alterations, epigenetic landscape remodeling, and metabolomic shifts. The impact of the altered TNBC tumor microenvironment (TME) on Tex is also a critical consideration. The production of exhausted CD8+ T-cells (CD8+ Tex) is positively correlated with poor prognosis and reduced response rates to immunotherapy in TNBC patients, underscoring the urgent need for the development of novel TNBC immunotherapeutic strategies that target the mechanisms of CD8+ T-cell exhaustion. This review delineates the dynamic trajectory of CD8+ T-cell exhaustion development in TNBC, provides an update on the latest research advancements in understanding its pathogenesis, and offers insights into potential immunotherapeutic strategies.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CD8+ T 细胞衰竭:三阴性乳腺癌 (TNBC) 免疫疗法的障碍。
CD8+T细胞衰竭已被确定为导致三阴性乳腺癌(TNBC)免疫抑制和免疫逃逸的重要因素。细胞衰竭导致的功能障碍表现为效应能力降低和抑制性受体(IR)持续表达。导致 CD8+ T 细胞衰竭的因素是多方面的,包括外部影响,如 IRs 上调、效应细胞因子减少,以及免疫细胞内部变化,包括转录组改变、表观遗传景观重塑和代谢组转变。TNBC 肿瘤微环境(TME)的改变对 Tex 的影响也是一个重要的考虑因素。CD8+T细胞衰竭(CD8+ Tex)的产生与TNBC患者预后不良和对免疫疗法反应率降低呈正相关,这突出表明迫切需要开发针对CD8+T细胞衰竭机制的新型TNBC免疫治疗策略。本综述描绘了TNBC中CD8+ T细胞衰竭的动态发展轨迹,提供了了解其发病机制的最新研究进展,并对潜在的免疫治疗策略提出了见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Biochimica et biophysica acta. Reviews on cancer
Biochimica et biophysica acta. Reviews on cancer 医学-生化与分子生物学
CiteScore
17.20
自引率
0.00%
发文量
138
审稿时长
33 days
期刊介绍: Biochimica et Biophysica Acta (BBA) - Reviews on Cancer encompasses the entirety of cancer biology and biochemistry, emphasizing oncogenes and tumor suppressor genes, growth-related cell cycle control signaling, carcinogenesis mechanisms, cell transformation, immunologic control mechanisms, genetics of human (mammalian) cancer, control of cell proliferation, genetic and molecular control of organismic development, rational anti-tumor drug design. It publishes mini-reviews and full reviews.
期刊最新文献
Roles of K(H)SRP in modulating gene transcription throughout cancer progression: Insights from cellular studies to clinical perspectives The curious case of type I interferon signaling in cancer Decoding secret role of mesenchymal stem cells in regulating cancer stem cells and drug resistance Structure, function, signaling pathways and clinical therapeutics: The translational potential of STAT3 as a target for cancer therapy The emerging role of extracellular vesicles and particles in prostate cancer diagnosis, and risk stratification
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1